NewEdge Advisors LLC Has $4.75 Million Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

NewEdge Advisors LLC raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.8% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 11,478 shares of the company’s stock after acquiring an additional 530 shares during the period. NewEdge Advisors LLC’s holdings in IDEXX Laboratories were worth $4,745,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Tidal Investments LLC grew its position in IDEXX Laboratories by 7.6% in the third quarter. Tidal Investments LLC now owns 6,310 shares of the company’s stock valued at $3,188,000 after purchasing an additional 444 shares in the last quarter. Franklin Resources Inc. increased its position in shares of IDEXX Laboratories by 2.5% in the third quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company’s stock valued at $675,259,000 after acquiring an additional 34,305 shares during the last quarter. American Trust acquired a new stake in shares of IDEXX Laboratories in the third quarter valued at about $757,000. Oddo BHF Asset Management Sas acquired a new position in IDEXX Laboratories during the third quarter valued at approximately $1,128,000. Finally, GAMMA Investing LLC boosted its position in IDEXX Laboratories by 3.3% during the fourth quarter. GAMMA Investing LLC now owns 1,533 shares of the company’s stock valued at $634,000 after purchasing an additional 49 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares of the company’s stock, valued at $3,781,645.28. The trade was a 54.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.98% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Trading Up 2.3 %

Shares of IDXX stock opened at $411.72 on Friday. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $548.88. The company has a market capitalization of $33.37 billion, a PE ratio of 38.59, a price-to-earnings-growth ratio of 3.41 and a beta of 1.50. The firm has a 50 day moving average price of $422.37 and a two-hundred day moving average price of $430.84. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on IDXX. Bank of America upped their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Piper Sandler upped their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. Morgan Stanley decreased their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. StockNews.com lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 12th. Finally, Barclays lifted their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $523.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.